Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Levilimab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.17 [0.73, 1.87]
1 study · 206 participants
Low

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.43]
1 study · 206 participants
Low